BRPI0813680A2 - AGENTES DE iRNA, COMPOSIÇÃO FARMACÊUTICA COMPREENDENDO OS MESMOS, BEM COMO SEU USO. - Google Patents

AGENTES DE iRNA, COMPOSIÇÃO FARMACÊUTICA COMPREENDENDO OS MESMOS, BEM COMO SEU USO.

Info

Publication number: BRPI0813680A2
Authority: BR; Brazil
Prior art keywords: well; pharmaceutical composition; same; irna agents; composition understanding
Prior art date: 2007-06-15

Application number

BRPI0813680-7A2A

Other languages

English (en)

Inventor

Gino Van Heeke

Emma Hickman

Henry Luke Danahay

Pamela Tan

Anke Geick

Hans-Peter Vornlacher

Original Assignee

Novartis Ag

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

2007-06-15

Filing date

2008-06-13

Publication date

2015-01-06

2008-06-13 Application filed by Novartis Ag filed Critical Novartis Ag

2015-01-06 Publication of BRPI0813680A2 publication Critical patent/BRPI0813680A2/pt

2018-02-06 Publication of BRPI0813680B1 publication Critical patent/BRPI0813680B1/pt

2018-08-28 Publication of BRPI0813680A8 publication Critical patent/BRPI0813680A8/pt

Classifications

- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
- C12N15/113—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
- C12N15/1138—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing against receptors or cell surface proteins
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7088—Compounds having three or more nucleosides or nucleotides
- A61K31/713—Double-stranded nucleic acids or oligonucleotides
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/06—Antiasthmatics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/12—Drugs for disorders of the metabolism for electrolyte homeostasis
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/08—Antiallergic agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/12—Antihypertensives
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2310/00—Structure or type of the nucleic acid
- C12N2310/10—Type of nucleic acid
- C12N2310/14—Type of nucleic acid interfering nucleic acids [NA]
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2310/00—Structure or type of the nucleic acid
- C12N2310/30—Chemical structure
- C12N2310/31—Chemical structure of the backbone
- C12N2310/315—Phosphorothioates
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2310/00—Structure or type of the nucleic acid
- C12N2310/30—Chemical structure
- C12N2310/32—Chemical structure of the sugar
- C12N2310/321—2'-O-R Modification
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2310/00—Structure or type of the nucleic acid
- C12N2310/30—Chemical structure
- C12N2310/32—Chemical structure of the sugar
- C12N2310/322—2'-R Modification
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2310/00—Structure or type of the nucleic acid
- C12N2310/30—Chemical structure
- C12N2310/35—Nature of the modification
- C12N2310/351—Conjugate
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2310/00—Structure or type of the nucleic acid
- C12N2310/30—Chemical structure
- C12N2310/35—Nature of the modification
- C12N2310/351—Conjugate
- C12N2310/3513—Protein; Peptide
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2310/00—Structure or type of the nucleic acid
- C12N2310/30—Chemical structure
- C12N2310/35—Nature of the modification
- C12N2310/351—Conjugate
- C12N2310/3515—Lipophilic moiety, e.g. cholesterol
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2310/00—Structure or type of the nucleic acid
- C12N2310/30—Chemical structure
- C12N2310/35—Nature of the modification
- C12N2310/352—Nature of the modification linked to the nucleic acid via a carbon atom
- C12N2310/3521—Methyl

Landscapes

Health & Medical Sciences (AREA)
Life Sciences & Earth Sciences (AREA)
Chemical & Material Sciences (AREA)
Engineering & Computer Science (AREA)
General Health & Medical Sciences (AREA)
Organic Chemistry (AREA)
Animal Behavior & Ethology (AREA)
Veterinary Medicine (AREA)
Public Health (AREA)
Medicinal Chemistry (AREA)
Pharmacology & Pharmacy (AREA)
Bioinformatics & Cheminformatics (AREA)
Genetics & Genomics (AREA)
General Chemical & Material Sciences (AREA)
Chemical Kinetics & Catalysis (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
Biomedical Technology (AREA)
Molecular Biology (AREA)
General Engineering & Computer Science (AREA)
Zoology (AREA)
Wood Science & Technology (AREA)
Biotechnology (AREA)
Biochemistry (AREA)
Epidemiology (AREA)
Pulmonology (AREA)
Physics & Mathematics (AREA)
Microbiology (AREA)
Plant Pathology (AREA)
Biophysics (AREA)
Communicable Diseases (AREA)
Oncology (AREA)
Heart & Thoracic Surgery (AREA)
Cardiology (AREA)
Virology (AREA)
Hematology (AREA)
Diabetes (AREA)
Urology & Nephrology (AREA)
Immunology (AREA)
Obesity (AREA)
Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

BRPI0813680A 2007-06-15 2008-06-13 composição compreendendo um agente de irna para alfa-enac, constituído por um fita senso e uma fita antissenso, e seu uso BRPI0813680A8 (pt)

Applications Claiming Priority (5)

Application Number	Priority Date	Filing Date	Title
EP07110376		2007-06-15
EP07110376.6		2007-06-15
EP07114265.7		2007-08-13
EP07114265		2007-08-13
PCT/EP2008/057476 WO2008152131A2 (en)	2007-06-15	2008-06-13	Rnai inhibition of alpha-enac expression

Publications (3)

Publication Number	Publication Date
BRPI0813680A2 true BRPI0813680A2 (pt)	2015-01-06
BRPI0813680B1 BRPI0813680B1 (pt)	2018-02-06
BRPI0813680A8 BRPI0813680A8 (pt)	2018-08-28

Family

ID=40130244

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
BRPI0813680A BRPI0813680A8 (pt)	2007-06-15	2008-06-13	composição compreendendo um agente de irna para alfa-enac, constituído por um fita senso e uma fita antissenso, e seu uso

Country Status (26)

Country	Link
US (12)	US7718632B2 (pt)
EP (7)	EP2224005B1 (pt)
JP (6)	JP5485146B2 (pt)
KR (2)	KR101653008B1 (pt)
CN (1)	CN101778941B (pt)
AR (1)	AR066984A1 (pt)
AU (1)	AU2008263876B2 (pt)
BR (1)	BRPI0813680A8 (pt)
CA (1)	CA2690674C (pt)
CL (1)	CL2008001756A1 (pt)
CO (1)	CO6251331A2 (pt)
CR (1)	CR11136A (pt)
CU (1)	CU23774A3 (pt)
EA (1)	EA200901653A1 (pt)
EC (1)	ECSP099794A (pt)
ES (6)	ES2432644T3 (pt)
GT (1)	GT200900315A (pt)
IL (1)	IL202366A0 (pt)
MA (1)	MA31564B1 (pt)
MX (1)	MX2009013609A (pt)
PE (1)	PE20090942A1 (pt)
SG (3)	SG169988A1 (pt)
SV (1)	SV2009003434A (pt)
TN (1)	TN2009000521A1 (pt)
TW (3)	TWI629063B (pt)
WO (1)	WO2008152131A2 (pt)

Families Citing this family (26)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
EP1532248B1 (en) *	2002-07-26	2009-04-01	Novartis Vaccines and Diagnostics, Inc.	Modified small interfering rna molecules and methods of use
KR100473148B1 (ko) *	2002-11-27	2005-03-10	(주)텔리언	버스트모드 패킷 전달을 위한 정합장치 및 방법
US8765704B1 (en)	2008-02-28	2014-07-01	Novartis Ag	Modified small interfering RNA molecules and methods of use
JP2008514242A (ja) *	2004-10-01	2008-05-08	ノバルティスヴァクシンズアンドダイアグノスティクス，インコーポレイテッド	改変型の小さい干渉ｒｎａ分子および使用方法
AR066984A1 (es) *	2007-06-15	2009-09-23	Novartis Ag	Inhibicion de la expresion de la subunidad alfa del canal epitelial de sodio (enac) por medio de arni (arn de interferencia)
MX2011005576A (es) *	2008-11-26	2011-08-17	Merck Sharp & Dohme	Inhibicion mediada por interferencia de ácido ribonucleico de la expresion del gen del canal de sodio epitelial (enac) usando acido nucleico corto de interferencia (anci).
EP2756845B1 (en) *	2009-04-03	2017-03-15	Dicerna Pharmaceuticals, Inc.	Methods and compositions for the specific inhibition of KRAS by asymmetric double-stranded RNA
CN103275978B (zh) *	2009-04-03	2014-10-29	百奥迈科生物技术有限公司	修饰的小干扰核酸及其制备方法
WO2010111891A1 (zh) *	2009-04-03	2010-10-07	北京大学	修饰的寡聚核酸分子及其制备方法和应用
US20120207818A1 (en) *	2009-07-14	2012-08-16	Shinohara Fumikazu	Composition for suppressing expression of target gene
DK3252068T3 (da) *	2009-10-12	2025-08-25	Larry J Smith	Metoder og sammensætninger til modulering af genekspression ved anvendelse af oligonukleotidbaserede lægemidler administreret in vivo eller in vitro
CN102686729B (zh)	2009-12-18	2015-09-23	箭头研究公司	用于治疗hsf1相关疾病的有机组合物
AR081082A1 (es)	2010-04-23	2012-06-06	Novartis Ag	Composiciones organicas para tratar enfermedades relacionadas con beta-enac
SG193990A1 (en) *	2011-04-08	2013-11-29	Bio Rad Laboratories	Pcr reaction mixtures with decreased non-specific activity
CA2871089A1 (en)	2011-04-20	2012-10-26	Smith Holdings, Llc	Methods and compositions for modulating gene expression using components that self assemble in cells and produce rnai activity
US9315813B2 (en) *	2011-06-21	2016-04-19	Alnylam Pharmaceuticals, Inc	Compositions and methods for inhibition of expression of apolipoprotein C-III (APOC3) genes
MX2014002536A (es)	2011-09-02	2014-09-01	Novartis Ag	Composiciones organicas para tratar enfermedades relacionadas con el factor de choque de calor 1 (hsf1).
IL266343B2 (en)	2016-11-01	2024-01-01	Arrowhead Pharmaceuticals Inc	Alpha-v beta-6 integrin ligands and uses thereof
KR20200024793A (ko) *	2017-07-06	2020-03-09	애로우헤드 파마슈티컬스 인코포레이티드	알파-ENaC의 발현을 억제하기 위한 RNAi 작용제 및 사용 방법
CN111372594A (zh) *	2017-10-31	2020-07-03	Ionis制药公司	ENaC表达的调节剂
SG11202002967SA (en)	2017-11-01	2020-05-28	Arrowhead Pharmaceuticals Inc	Integrin ligands and uses thereof
CN109364248B (zh) *	2018-10-16	2021-05-18	哈尔滨医科大学	ENaC及其抑制剂在预防、缓解和/或治疗动脉粥样硬化中的应用
WO2021041776A1 (en) *	2019-08-30	2021-03-04	United States Government As Represented By The Department Of Veterans Affairs	Liposomal troponoid compound formulations
US12415840B2 (en)	2020-02-21	2025-09-16	Brookhaven Science Associates, Llc	Modified form of oleosin that when expressed in plants leads to increased triacylglycerol (oil) accumulation
BR112023020626A2 (pt)	2021-04-08	2023-12-19	Arrowhead Pharmaceuticals Inc	Agentes de rnai para inibir a expressão do receptor para produtos finais de glicação avançada, composições dos mesmos e métodos de uso
US11957178B2 (en)	2021-11-15	2024-04-16	Apackaging Group Llc	Aerosol actuator

Family Cites Families (58)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US4426330A (en) *	1981-07-20	1984-01-17	Lipid Specialties, Inc.	Synthetic phospholipid compounds
US4534899A (en) *	1981-07-20	1985-08-13	Lipid Specialties, Inc.	Synthetic phospholipid compounds
US4522811A (en)	1982-07-08	1985-06-11	Syntex (U.S.A.) Inc.	Serial injection of muramyldipeptides and liposomes enhances the anti-infective activity of muramyldipeptides
US4837026A (en) *	1985-10-03	1989-06-06	Rajakhyaksha Vithal J	Transdermal and systemic preparation and method
DE3604625C2 (de) *	1986-02-14	1994-01-20	Bmw Rolls Royce Gmbh	Gasturbine
US4837028A (en) *	1986-12-24	1989-06-06	Liposome Technology, Inc.	Liposomes with enhanced circulation time
US4920016A (en)	1986-12-24	1990-04-24	Linear Technology, Inc.	Liposomes with enhanced circulation time
US5451670A (en) *	1987-12-09	1995-09-19	City Of Hope	Restriction fragment length polymorphism test for haplotyping domesticated fowl
GB8824593D0 (en)	1988-10-20	1988-11-23	Royal Free Hosp School Med	Liposomes
US5013566A (en) *	1988-12-19	1991-05-07	Sampson Michael James	Process for obtaining improved yields from plants used for hay making by using a coating agent
US5328470A (en) *	1989-03-31	1994-07-12	The Regents Of The University Of Michigan	Treatment of diseases by site-specific instillation of cells or site-specific transformation of cells and kits therefor
US5225212A (en) *	1989-10-20	1993-07-06	Liposome Technology, Inc.	Microreservoir liposome composition and method
US5013556A (en) *	1989-10-20	1991-05-07	Liposome Technology, Inc.	Liposomes with enhanced circulation time
US5356633A (en) *	1989-10-20	1994-10-18	Liposome Technology, Inc.	Method of treatment of inflamed tissues
US5665710A (en) *	1990-04-30	1997-09-09	Georgetown University	Method of making liposomal oligodeoxynucleotide compositions
JP3220180B2 (ja) *	1991-05-23	2001-10-22	三菱化学株式会社	薬剤含有タンパク質結合リポソーム
JP3351476B2 (ja) *	1993-01-22	2002-11-25	三菱化学株式会社	リン脂質誘導体及びそれを含有するリポソーム
CA2156288C (en) *	1993-02-19	2005-10-18	Junichi Yano	Glycerol derivative, device and pharmaceutical composition
US5395619A (en)	1993-03-03	1995-03-07	Liposome Technology, Inc.	Lipid-polymer conjugates and liposomes
US5540935A (en) *	1993-12-06	1996-07-30	Nof Corporation	Reactive vesicle and functional substance-fixed vesicle
JP3543347B2 (ja) *	1994-01-24	2004-07-14	日本油脂株式会社	点火薬造粒物の製造方法
US5543152A (en) *	1994-06-20	1996-08-06	Inex Pharmaceuticals Corporation	Sphingosomes for enhanced drug delivery
US5820873A (en)	1994-09-30	1998-10-13	The University Of British Columbia	Polyethylene glycol modified ceramide lipids and liposome uses thereof
US5756122A (en)	1995-06-07	1998-05-26	Georgetown University	Liposomally encapsulated nucleic acids having high entrapment efficiencies, method of manufacturer and use thereof for transfection of targeted cells
ATE247971T1 (de)	1995-08-01	2003-09-15	Novartis Erfind Verwalt Gmbh	Liposomale oligonukleotidzusammensetzungen
US5858397A (en)	1995-10-11	1999-01-12	University Of British Columbia	Liposomal formulations of mitoxantrone
US5998203A (en)	1996-04-16	1999-12-07	Ribozyme Pharmaceuticals, Inc.	Enzymatic nucleic acids containing 5'-and/or 3'-cap structures
US5994316A (en)	1996-02-21	1999-11-30	The Immune Response Corporation	Method of preparing polynucleotide-carrier complexes for delivery to cells
US6218108B1 (en) *	1997-05-16	2001-04-17	Research Corporation Technologies, Inc.	Nucleoside analogs with polycyclic aromatic groups attached, methods of synthesis and uses therefor
US5865710A (en) *	1996-08-01	1999-02-02	Wilson-Hyde; Cynthia	Step aerobic platform
AU742598B2 (en) *	1997-03-11	2002-01-10	Yale University	Method to diagnose and treat pathological conditions resulting from deficient ion transport such as pseudohypoaldosteronism type-1
AU731909B2 (en) *	1997-07-01	2001-04-05	Isis Pharmaceuticals, Inc.	Compositions and methods for the delivery of oligonucleotides via the alimentary canal
US5976849A (en) *	1998-02-05	1999-11-02	Zeneca Limited	Human E3 ubiquitin protein ligase
DE60040274D1 (de)	1999-03-10	2008-10-30	Phogen Ltd	Verabreichung von nukleinsäuren und proteinen an zellen
US20040259247A1 (en) *	2000-12-01	2004-12-23	Thomas Tuschl	Rna interference mediating small rna molecules
CN1526025A (zh)	2001-05-16	2004-09-01	��˹��ŵ��	作为预后和治疗靶标的乳腺癌中表达的基因
WO2003057847A2 (en)	2001-12-31	2003-07-17	Algos Therapeutics , Inc.	METHODS AND MATERIALS FOR MODULATING ENaC-BETA
EP1532248B1 (en)	2002-07-26	2009-04-01	Novartis Vaccines and Diagnostics, Inc.	Modified small interfering rna molecules and methods of use
JP2004121218A (ja)	2002-08-06	2004-04-22	Jenokkusu Soyaku Kenkyusho:Kk	気管支喘息または慢性閉塞性肺疾患の検査方法
GB0218970D0 (en)	2002-08-14	2002-09-25	Creative Peptides Sweden Ab	Fragments of Insulin c-peptide
AU2003295600A1 (en) *	2002-11-14	2004-06-15	Dharmacon, Inc.	Functional and hyperfunctional sirna
US20060275770A1 (en)	2002-11-27	2006-12-07	Daniel Bednarik	Heart failure gene determination and therapeutic screening
WO2004050694A1 (en)	2002-11-29	2004-06-17	Basf Aktiengesellschaft	Methods for the production of methionine
DE10305213A1 (de)	2003-02-07	2004-08-26	Florian Prof. Dr.med. Lang	Verwendung eines neuen Polymorphismus im hsgk1-Gen zur Diagnose der Hypertonie und Verwendung der sgk-Genfamilie zur Diagnose und Therapie des Long-Q/T-Syndroms
US20050095225A1 (en) *	2003-03-31	2005-05-05	Engelhardt John F.	Compounds and methods for pharmico-gene therapy of epithelial sodium channel associated disorders
US7723509B2 (en) *	2003-04-17	2010-05-25	Alnylam Pharmaceuticals	IRNA agents with biocleavable tethers
WO2004094636A1 (en)	2003-04-24	2004-11-04	Galapagos Genomics N.V.	Effective sirna knock-down constructs
US20050256071A1 (en) *	2003-07-15	2005-11-17	California Institute Of Technology	Inhibitor nucleic acids
JP4530335B2 (ja) *	2004-02-03	2010-08-25	独立行政法人科学技術振興機構	膀胱に発現する上皮型ナトリウムチャネルに対する阻害薬
CN101052717A (zh) *	2004-05-11	2007-10-10	α基因株式会社	诱发rna干扰的多核苷酸以及使用该多核苷酸的基因表达抑制方法
SE0402832D0 (sv) *	2004-11-18	2004-11-18	Astrazeneca Ab	Methods
US20060166234A1 (en) *	2004-11-22	2006-07-27	Barbara Robertson	Apparatus and system having dry control gene silencing compositions
ATE544774T1 (de) *	2004-12-14	2012-02-15	Alnylam Pharmaceuticals Inc	Rnai-modulation von mll-af4 und verwendungen dafür
WO2007051303A1 (en) *	2005-11-02	2007-05-10	Protiva Biotherapeutics, Inc.	MODIFIED siRNA MOLECULES AND USES THEREOF
WO2007070509A2 (en) *	2005-12-13	2007-06-21	University Of Pittsburgh-Of The Commonwealth System Of Higher Education	Epithelial sodium channel inhibiting agents and uses therefor
BRPI0715375A2 (pt)	2006-08-18	2013-06-18	Hoffmann La Roche	policonjugados para distribuiÇço in vivo de polinucleotÍdeos
WO2008043561A2 (en)	2006-10-11	2008-04-17	MAX-PLANCK-Gesellschaft zur Förderung der Wissenschaften e.V.	Influenza targets
AR066984A1 (es)	2007-06-15	2009-09-23	Novartis Ag	Inhibicion de la expresion de la subunidad alfa del canal epitelial de sodio (enac) por medio de arni (arn de interferencia)

2008
- 2008-06-12 AR ARP080102518A patent/AR066984A1/es not_active Application Discontinuation
- 2008-06-13 BR BRPI0813680A patent/BRPI0813680A8/pt not_active IP Right Cessation
- 2008-06-13 ES ES10163500T patent/ES2432644T3/es active Active
- 2008-06-13 SG SG201101084-0A patent/SG169988A1/en unknown
- 2008-06-13 PE PE2008001013A patent/PE20090942A1/es not_active Application Discontinuation
- 2008-06-13 EP EP10163498.8A patent/EP2224005B1/en active Active
- 2008-06-13 TW TW105120348A patent/TWI629063B/zh not_active IP Right Cessation
- 2008-06-13 EP EP10163500.1A patent/EP2223693B1/en active Active
- 2008-06-13 EP EP10163501.9A patent/EP2223694B1/en active Active
- 2008-06-13 EP EP10163499.6A patent/EP2223692B1/en active Active
- 2008-06-13 ES ES10163502T patent/ES2432532T3/es active Active
- 2008-06-13 AU AU2008263876A patent/AU2008263876B2/en not_active Ceased
- 2008-06-13 SG SG10201404955RA patent/SG10201404955RA/en unknown
- 2008-06-13 ES ES10163496T patent/ES2432643T3/es active Active
- 2008-06-13 EP EP10163502.7A patent/EP2223695B1/en active Active
- 2008-06-13 CN CN2008801032623A patent/CN101778941B/zh active Active
- 2008-06-13 EA EA200901653A patent/EA200901653A1/ru unknown
- 2008-06-13 KR KR1020107000840A patent/KR101653008B1/ko active Active
- 2008-06-13 EP EP10163496.2A patent/EP2224004B1/en active Active
- 2008-06-13 CL CL2008001756A patent/CL2008001756A1/es unknown
- 2008-06-13 ES ES10163498.8T patent/ES2439277T3/es active Active
- 2008-06-13 ES ES10163501T patent/ES2432158T3/es active Active
- 2008-06-13 MX MX2009013609A patent/MX2009013609A/es active IP Right Grant
- 2008-06-13 SG SG10201601846VA patent/SG10201601846VA/en unknown
- 2008-06-13 CA CA2690674A patent/CA2690674C/en active Active
- 2008-06-13 TW TW097122240A patent/TWI444474B/zh not_active IP Right Cessation
- 2008-06-13 TW TW103118914A patent/TWI552753B/zh not_active IP Right Cessation
- 2008-06-13 JP JP2010511658A patent/JP5485146B2/ja not_active Expired - Fee Related
- 2008-06-13 ES ES10163499T patent/ES2432157T3/es active Active
- 2008-06-13 EP EP08761002A patent/EP2171059A2/en not_active Withdrawn
- 2008-06-13 WO PCT/EP2008/057476 patent/WO2008152131A2/en not_active Ceased
- 2008-06-13 KR KR1020167023121A patent/KR101821081B1/ko not_active Expired - Fee Related
- 2008-06-16 US US12/140,112 patent/US7718632B2/en active Active
2009
- 2009-11-26 IL IL202366A patent/IL202366A0/en unknown
- 2009-12-02 CR CR11136A patent/CR11136A/es not_active Application Discontinuation
- 2009-12-11 EC EC2009009794A patent/ECSP099794A/es unknown
- 2009-12-11 CO CO09142201A patent/CO6251331A2/es not_active Application Discontinuation
- 2009-12-11 TN TNP2009000521A patent/TN2009000521A1/fr unknown
- 2009-12-11 GT GT200900315A patent/GT200900315A/es unknown
- 2009-12-14 SV SV2009003434A patent/SV2009003434A/es unknown
- 2009-12-15 CU CU20090215A patent/CU23774A3/es not_active IP Right Cessation
2010
- 2010-01-06 US US12/683,146 patent/US9074212B2/en active Active
- 2010-01-07 MA MA32484A patent/MA31564B1/fr unknown
- 2010-04-30 US US12/771,566 patent/US8119612B2/en active Active
- 2010-04-30 US US12/771,614 patent/US8168606B2/en not_active Expired - Fee Related
- 2010-04-30 US US12/771,470 patent/US7943592B2/en active Active
- 2010-04-30 US US12/771,518 patent/US7939508B2/en active Active
2014
- 2014-02-19 JP JP2014029519A patent/JP5719047B2/ja not_active Expired - Fee Related
2015
- 2015-03-19 JP JP2015055783A patent/JP6193906B2/ja not_active Expired - Fee Related
- 2015-06-03 US US14/729,104 patent/US9476052B2/en active Active
2016
- 2016-09-09 US US15/260,824 patent/US9914927B2/en active Active
2017
- 2017-08-01 JP JP2017149211A patent/JP6680728B2/ja not_active Expired - Fee Related
2018
- 2018-01-18 US US15/874,396 patent/US10544418B2/en active Active
2020
- 2020-01-24 US US16/752,325 patent/US11208662B2/en not_active Expired - Fee Related
- 2020-03-17 JP JP2020046007A patent/JP7157775B2/ja active Active
2021
- 2021-12-23 US US17/560,475 patent/US20220112505A1/en not_active Abandoned
2022
- 2022-04-05 US US17/713,763 patent/US20220235361A1/en not_active Abandoned
- 2022-10-07 JP JP2022162309A patent/JP2022188234A/ja active Pending

Also Published As

Publication number	Publication date
JP6680728B2 (ja)	2020-04-15
CO6251331A2 (es)	2011-02-21
KR101653008B1 (ko)	2016-08-31
CA2690674A1 (en)	2008-12-18
EP2223693B1 (en)	2013-07-24
EP2223692A1 (en)	2010-09-01
CU23774A3 (es)	2012-02-15
JP2020094063A (ja)	2020-06-18
US20220235361A1 (en)	2022-07-28
SG169988A1 (en)	2011-04-29
SG10201601846VA (en)	2016-04-28
US7943592B2 (en)	2011-05-17
US20100210514A1 (en)	2010-08-19
US7718632B2 (en)	2010-05-18
EA200901653A1 (ru)	2010-06-30
JP2015145393A (ja)	2015-08-13
JP2014129373A (ja)	2014-07-10
US9476052B2 (en)	2016-10-25
US11208662B2 (en)	2021-12-28
EP2223694B1 (en)	2013-07-24
TW201636027A (zh)	2016-10-16
US10544418B2 (en)	2020-01-28
AU2008263876A1 (en)	2008-12-18
JP2010530369A (ja)	2010-09-09
US20100216971A1 (en)	2010-08-26
BRPI0813680A8 (pt)	2018-08-28
JP5485146B2 (ja)	2014-05-07
AU2008263876B2 (en)	2012-04-12
SG10201404955RA (en)	2014-10-30
US20150284726A1 (en)	2015-10-08
US8119612B2 (en)	2012-02-21
EP2223693A1 (en)	2010-09-01
TW200911989A (en)	2009-03-16
ES2432644T3 (es)	2013-12-04
ES2432643T3 (es)	2013-12-04
EP2223695B1 (en)	2013-07-24
CL2008001756A1 (es)	2009-02-20
CN101778941A (zh)	2010-07-14
CN101778941B (zh)	2013-05-22
US20100190714A1 (en)	2010-07-29
KR101821081B1 (ko)	2018-01-23
ES2432158T3 (es)	2013-12-02
US20100216972A1 (en)	2010-08-26
JP6193906B2 (ja)	2017-09-06
US20200157550A1 (en)	2020-05-21
US7939508B2 (en)	2011-05-10
JP2017222704A (ja)	2017-12-21
US20090156529A1 (en)	2009-06-18
EP2223695A1 (en)	2010-09-01
ECSP099794A (es)	2010-01-29
US9914927B2 (en)	2018-03-13
US20160376599A1 (en)	2016-12-29
GT200900315A (es)	2011-10-05
US9074212B2 (en)	2015-07-07
TN2009000521A1 (en)	2011-03-31
JP5719047B2 (ja)	2015-05-13
JP7157775B2 (ja)	2022-10-20
PE20090942A1 (es)	2009-08-05
CR11136A (es)	2010-01-20
WO2008152131A3 (en)	2009-05-28
US20180148726A1 (en)	2018-05-31
MX2009013609A (es)	2010-01-20
JP2022188234A (ja)	2022-12-20
SV2009003434A (es)	2011-03-23
EP2224004B1 (en)	2013-07-24
ES2439277T3 (es)	2014-01-22
ES2432157T3 (es)	2013-12-02
US20100210513A1 (en)	2010-08-19
KR20160105530A (ko)	2016-09-06
MA31564B1 (fr)	2010-08-02
EP2224005B1 (en)	2013-09-11
TWI552753B (zh)	2016-10-11
CA2690674C (en)	2018-09-11
EP2171059A2 (en)	2010-04-07
EP2224005A1 (en)	2010-09-01
BRPI0813680B1 (pt)	2018-02-06
EP2223692B1 (en)	2013-07-24
AR066984A1 (es)	2009-09-23
EP2224004A1 (en)	2010-09-01
KR20100039335A (ko)	2010-04-15
TWI444474B (zh)	2014-07-11
WO2008152131A2 (en)	2008-12-18
IL202366A0 (en)	2011-08-01
US8168606B2 (en)	2012-05-01
TWI629063B (zh)	2018-07-11
EP2223694A1 (en)	2010-09-01
TW201524510A (zh)	2015-07-01
US20220112505A1 (en)	2022-04-14
ES2432532T3 (es)	2013-12-04

Publication	Publication Date	Title
BRPI0813680A2 (pt)	2015-01-06	AGENTES DE iRNA, COMPOSIÇÃO FARMACÊUTICA COMPREENDENDO OS MESMOS, BEM COMO SEU USO.
BR112012004335A2 (pt)	2015-09-08	composto, composição farmacêutica, e, uso do composto.
BRPI0818459A2 (pt)	2015-04-14	Composição farmacêutica adequada para uso oftálmico.
SI1998783T1 (sl)	2014-09-30	Oftalmični sestavki, ki obsegajo providon-jod
HUE042286T2 (hu)	2019-06-28	Tûvel szerelt, elõre töltött belövõ fecskendõ
BRPI0718266A2 (pt)	2014-01-07	Compostos heterocíclicos como agentes anti-inflamatórios.
HRP20151058T1 (xx)	2015-12-04	Ariloazol-2-il-cijanoetilamino-spojevi, postupak njihove proizvodnje i postupak njihove uporabe
BRPI0815709A2 (pt)	2017-06-13	composro, composição farmacêutica, e, uso de um composto.
BRPI0815979A2 (pt)	2017-06-13	compostos e composições com inibidores de quinase, bem como uso dos mesmos
BRPI0921389A2 (pt)	2018-06-19	seringa de um só uso, de inutilização automática
BRPI0910503A2 (pt)	2015-09-29	compostos, composições farmacêuticas e respectivos usos.
BRPI0821668A2 (pt)	2015-06-16	Uso
HRP20150107T1 (xx)	2015-03-13	Derivati dioksabiciklo[3.2.1]oktan-2,3,4-triola
BRPI0813908A2 (pt)	2015-07-14	Seringa com mecanismo de desativar
BRPI1010621A2 (pt)	2016-06-21	derivado de imidazoquinolinonas, sua composição farmacêutica e seu uso
IT1390737B1 (it)	2011-09-23	Macchina per la realizzazione di articoli assorbenti.
BRPI0808172A2 (pt)	2014-11-04	Compostos heterocíclicos, composições compreendendo-os e métodos de seu uso.
BRPI0810654A2 (pt)	2014-11-04	Tiadiazoliloxifenilamidinas e o seu uso como fungicidas.
BRPI0911772A2 (pt)	2017-06-27	composto, composição farmacêutica, e, uso do composto.
BRPI0813587A2 (pt)	2014-12-30	Composto, uso do mesmo, e, composição farmacêutica
BRPI0811444A2 (pt)	2014-10-29	Derivados de azetidina e seu uso como antagonistas da prostaglandina e2.
BRPI0813453A2 (pt)	2014-12-23	3-ciclopropil-4-(3-tiobenzoil)pirazol e seu uso como herbicida.
BRPI0816679A2 (pt)	2015-03-17	Derivados de ftalazinona.
BR112013023575A2 (pt)	2016-12-06	derivado de octaidrotienoquinolina, composição farmacêutica compreendendo o derivado, e uso destes
FR2923713B1 (fr)	2010-09-10	Composition reductrice epaissie.

Legal Events

Date	Code	Title	Description
2015-10-13	B07D	Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette]
2017-03-21	B07E	Notification of approval relating to section 229 industrial property law [chapter 7.5 patent gazette]
2017-06-20	B07A	Application suspended after technical examination (opinion) [chapter 7.1 patent gazette]
2017-11-07	B09A	Decision: intention to grant [chapter 9.1 patent gazette]
2018-02-06	B16A	Patent or certificate of addition of invention granted [chapter 16.1 patent gazette]
2025-04-08	B21F	Lapse acc. art. 78, item iv - on non-payment of the annual fees in time	Free format text: REFERENTE A 17A ANUIDADE.
2025-07-29	B24J	Lapse because of non-payment of annual fees (definitively: art 78 iv lpi, resolution 113/2013 art. 12)	Free format text: EM VIRTUDE DA EXTINCAO PUBLICADA NA RPI 2831 DE 08-04-2025 E CONSIDERANDO AUSENCIA DE MANIFESTACAO DENTRO DOS PRAZOS LEGAIS, INFORMO QUE CABE SER MANTIDA A EXTINCAO DA PATENTE E SEUS CERTIFICADOS, CONFORME O DISPOSTO NO ARTIGO 12, DA RESOLUCAO 113/2013.